Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Price Target at $298.09

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have been assigned an average recommendation of “Moderate Buy” from the twenty-four analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have issued a buy rating on the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $298.09.

Several research firms have recently weighed in on ALNY. William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Tuesday, November 19th. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. Raymond James lifted their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Finally, Barclays upped their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now owns 15,705 shares of the company’s stock, valued at approximately $3,941,955. This trade represents a 10.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Yvonne Greenstreet sold 5,219 shares of the company’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the completion of the transaction, the chief executive officer now owns 78,880 shares of the company’s stock, valued at $19,797,302.40. The trade was a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,122 shares of company stock worth $2,540,455 over the last three months. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ashton Thomas Private Wealth LLC purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $26,000. Huntington National Bank boosted its position in shares of Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management purchased a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at $29,000. Washington Trust Advisors Inc. bought a new stake in Alnylam Pharmaceuticals in the third quarter worth $42,000. Finally, True Wealth Design LLC raised its stake in Alnylam Pharmaceuticals by 15,300.0% during the third quarter. True Wealth Design LLC now owns 154 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 153 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.1 %

Alnylam Pharmaceuticals stock opened at $245.44 on Wednesday. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The stock has a fifty day simple moving average of $267.01 and a two-hundred day simple moving average of $249.57. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The firm has a market cap of $31.66 billion, a price-to-earnings ratio of -93.68 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period last year, the firm earned $1.15 EPS. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals will post -2.21 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.